

# \$9.1+ Billion Antacids Market Poised for Steady Growth: Key Trends and Projections to 2032

#### Antacids Market Research, 2032

The global antacids market is projected to witness steady growth from \$6.7 billion in 2022 to \$9.1 billion by 2032, driven by various market dynamics and emerging trends.



\$9.1+ Billion Antacids Market Poised for Steady Growth: Key Trends and Projections to 2032

### **Key Market Insights**

- Market Size and Growth:
- 2022 Market Value: \$6.7 billion
- Projected 2032 Market Value: \$9.1 billion
- CAGR: 3.1% from 2023 to 2032
- Antacid Functionality:
- Neutralizes stomach acid.
- Contains active ingredients like aluminum, calcium, magnesium, or sodium bicarbonate.
- Treats symptoms such as acid reflux, heartburn, and indigestion.

## Market Dynamics

- Drivers:
- Increasing prevalence of gastroesophageal reflux disease (GERD).
- Rising awareness about digestive health.
- Unhealthy eating habits and sedentary lifestyles.
- Accessibility of over-the-counter (OTC) antacids.
- · Restraints:
- Emergence of more effective treatments such as proton pump inhibitors (PPIs) and H2 receptor antagonists.

- Opportunities:
- Lifestyle changes leading to increased demand for antacids.
- COVID-19 pandemic impact with increased gastrointestinal symptoms.

### Segmental Overview

- By Mechanism of Action:
- Non-Systemic Antacids: Largest market share in 2022; fastest growth projected.
- Systemic Antacids: Lesser market share due to consumer preference for non-systemic options.
- By Formulation Type:
- Tablets: Dominated market in 2022; popular for convenience and variety.
- Liquids: Fastest growing segment; preferred for ease of use and palatability.
- By Distribution Channel:
- Drug Stores & Retail Pharmacies: Dominated market due to convenience.
- Online Providers: Fastest growing segment; driven by e-commerce popularity.

# Regional Analysis

- · North America:
- · Largest market share in 2022.
- Growth driven by well-developed healthcare infrastructure and high prevalence of gastrointestinal diseases.
- · Asia-Pacific:
- · Highest growth rate projected.
- Driven by increasing healthcare expenditure and growing awareness about heartburn and gastrointestinal issues.

# Competitive Landscape

- Major Players:
- Abbott Laboratories
- Alkem Laboratories Ltd.
- Cipla Ltd.
- Bayer AG
- Haleon Plc
- · Infirst Healthcare Inc.
- Pfizer Inc.
- Prestige Consumer Healthcare Inc.
- Reckitt Benckiser Group PLC
- WellSpring Pharmaceutical Corporation
- Other Important Players:
- Major Pharmaceuticals
- Topco Associates, LLC

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X

This press release can be viewed online at: https://www.einpresswire.com/article/728267963

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.